OKYO Pharma Ltd
urcosimod
neuropathic corneal pain (NCP)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on urcosimod for neuropathic corneal pain (NCP) is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 12h ago
“With urcosimod’s Fast Track status, promising Phase 2 data, and FDA alignment, we are advancing toward pivotal trials and potential commercialization.”